Active Investment Focus Kurma Partners maintains a dynamic investment portfolio within healthcare, actively funding innovative companies in radiopharmaceuticals, 3D imaging, and oncology, indicating ongoing opportunities to offer tailored financial and strategic partnerships in emerging biotech and medtech sectors.

Funding Growth Opportunities With recent successful fund closings reaching €154 million and multiple investments in Series B and Series A rounds, Kurma’s capital deployment presents prospects for sourcing additional funding or co-investment opportunities aligned with its health tech and biotech priorities.

Technology Integration Kurma Partners’ involvement with portfolio companies leveraging advanced medical imaging and digital health solutions highlights a potential need for innovative technology solutions, consulting, or partnerships to enhance their portfolio companies’ capabilities.

Strategic Partnerships Recent collaborations with industry leaders like Samsung BioLogics suggest openness to strategic alliances that support drug development and manufacturing, offering avenues for sales focused on biotech service providers, contract research, and manufacturing organizations.

Market Expansion Readiness Kurma’s focus on European healthcare innovation and growth through targeted investments signifies readiness to expand their portfolio, creating opportunities to introduce scalable healthcare solutions, digital health tools, or specialized biotech products that align with their investment themes.